Madrigal pharmaceuticals provides business and clinical updates and reports 2021 fourth quarter and full year financial results

Conshohocken, pa., feb. 24, 2022 (globe newswire) -- madrigal pharmaceuticals, inc. (nasdaq:mdgl), a clinical-stage biopharmaceutical company pursuing novel therapeutics for non-alcoholic steatohepatitis (nash), today provides a summary of corporate accomplishments and reports its fourth quarter and full year 2021 financial results.
MDGL Ratings Summary
MDGL Quant Ranking